CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis
Egile Nagusiak: | , , , , , , , , , , |
---|---|
Formatua: | Conference item |
Hizkuntza: | English |
Argitaratua: |
Wiley
2022
|
Gaia: |
---|